From Motely Fool on AOL (Subject: White Paper)
(Contact Zonagen for copy)
----------------------------------------------
Subject: White paper
Date: 12/31/97 3:46 PM Eastern Standard Time
Just finished reading the paper. It read well, and was basically just what Joe said it would be in the last conference call. I was a good cronological explanation of the development of Vasomax. It does go into some detail of all the patent issues, trial results, and marketing strategies, but really does not expand on most of the data and information we have already seen. This I'm sure is at the request/insistance of SGP. Obviously, for the
purpose of not giving the competition to much information.
For all those posters who have not been involved with Zonagen a long time, this is a must read paper. It will bring you up to date on Vasomax and refute much of the BS being spouted by the short attackers here and SI. Many of those who attack Zonagen make reference to this and that, but do not post what these references say or mean. They just make comments like "Well, what about ZON-301?", or make reference to trial patients having had heart
attacks, with no substanciation. Well, facts are there were not heart attacks. What the short attackers would have you beleive is that, I beleive in the Zon-301 study, where they were testing a 80mg dose, (which is twice the recomended dose), one patient experienced an increase in heart rate and a decrease in BP of more that 30%, and one patient experienced chest pain. A far cry from a heart attack. These were the only significant adverse effects in
hundreds of patients. They were given the 80mg dose to test the effects of someone voluntarily doubling the recomended dosage. No other serious adverse effects were reported in the trial.
Everyone investing in Zonagen should read this paper to help give you a good base of information on the development of Vasomax. Do your own DD from then on, and don't get caught listned to unsubstaciated attacks and taking them for fact.. |
